LT3366688T - Pakeistieji pirazolopirimidinai, kaip gliukocerebrozidazės aktyvatoriai - Google Patents
Pakeistieji pirazolopirimidinai, kaip gliukocerebrozidazės aktyvatoriaiInfo
- Publication number
- LT3366688T LT3366688T LTEP18165005.2T LT18165005T LT3366688T LT 3366688 T LT3366688 T LT 3366688T LT 18165005 T LT18165005 T LT 18165005T LT 3366688 T LT3366688 T LT 3366688T
- Authority
- LT
- Lithuania
- Prior art keywords
- substituted pyrazolopyrimidines
- glucocerebrosidase
- activators
- glucocerebrosidase activators
- pyrazolopyrimidines
- Prior art date
Links
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
- 102000004547 Glucosylceramidase Human genes 0.000 title 1
- 108010017544 Glucosylceramidase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42094610P | 2010-12-08 | 2010-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3366688T true LT3366688T (lt) | 2022-05-25 |
Family
ID=45498099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP18165005.2T LT3366688T (lt) | 2010-12-08 | 2011-12-08 | Pakeistieji pirazolopirimidinai, kaip gliukocerebrozidazės aktyvatoriai |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9353117B2 (enExample) |
| EP (2) | EP3366688B1 (enExample) |
| JP (1) | JP6154746B2 (enExample) |
| KR (1) | KR101931224B1 (enExample) |
| CN (1) | CN103534255B (enExample) |
| AU (1) | AU2011338377B2 (enExample) |
| BR (1) | BR112013014242B1 (enExample) |
| CA (1) | CA2820362C (enExample) |
| CY (1) | CY1125186T1 (enExample) |
| DK (2) | DK2649075T3 (enExample) |
| ES (2) | ES2912284T3 (enExample) |
| HR (1) | HRP20220512T1 (enExample) |
| HU (1) | HUE038635T2 (enExample) |
| IL (2) | IL226767B (enExample) |
| LT (1) | LT3366688T (enExample) |
| MX (2) | MX385600B (enExample) |
| PL (2) | PL3366688T3 (enExample) |
| PT (2) | PT2649075T (enExample) |
| RS (1) | RS63320B1 (enExample) |
| RU (1) | RU2603637C2 (enExample) |
| SI (2) | SI3366688T1 (enExample) |
| TR (1) | TR201810523T4 (enExample) |
| WO (1) | WO2012078855A1 (enExample) |
| ZA (1) | ZA201304215B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3366688B1 (en) | 2010-12-08 | 2022-02-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
| CA2839703A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| AP2013007331A0 (en) | 2011-06-24 | 2013-12-31 | Amgen Inc | TRPM8 antagonists and their use in treatments |
| JP6073343B2 (ja) * | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| LT3486245T (lt) | 2012-12-07 | 2021-08-25 | Vertex Pharmaceuticals Incorporated | 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| AU2015271030B2 (en) | 2014-06-05 | 2019-05-16 | Vertex Pharmaceuticals Incorporated | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| CN107108638A (zh) | 2014-11-03 | 2017-08-29 | 拜耳制药股份公司 | 哌啶基吡唑并嘧啶酮及其用途 |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| IL252053B2 (en) | 2014-11-06 | 2024-04-01 | Lysosomal Therapeutics Inc | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| CA2966581A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| JP2018522872A (ja) * | 2015-07-01 | 2018-08-16 | ノースウェスタン ユニバーシティ | 置換４−メチルピロロ［１，２−ａ］ピリミジン−８−カルボキサミド化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| EP3344625A4 (en) * | 2015-09-04 | 2019-03-27 | Lysosomal Therapeutics Inc. | THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE |
| EP3344632A4 (en) * | 2015-09-04 | 2019-03-20 | Lysosomal Therapeutics Inc. | Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders |
| CA2998469C (en) | 2015-09-14 | 2025-12-09 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
| WO2017161137A1 (en) * | 2016-03-16 | 2017-09-21 | Lysosomal Therapeutics Inc. | Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP3440081A4 (en) * | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| US20190389865A1 (en) * | 2016-05-05 | 2019-12-26 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| EP3452481A4 (en) | 2016-05-05 | 2020-02-26 | Lysosomal Therapeutics Inc. | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN109890829B (zh) * | 2016-11-02 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| DK3658557T3 (da) * | 2017-07-28 | 2024-07-29 | Takeda Pharmaceuticals Co | Tyk2-inhibitorer og anvendelser deraf |
| JP2020530000A (ja) | 2017-08-02 | 2020-10-15 | ノースウエスタン ユニバーシティ | 置換縮合ピリミジン化合物およびその使用 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| US11459325B2 (en) | 2018-01-31 | 2022-10-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| US10882865B2 (en) | 2018-08-31 | 2021-01-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
| EP3849981B1 (en) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| HRP20230409T1 (hr) | 2018-10-05 | 2023-07-07 | Forma Therapeutics, Inc. | Fuzionirani pirolini koji djeluju kao inhibitori ubikvitin specifične proteaze 30 (usp30) |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| KR102821711B1 (ko) * | 2019-08-21 | 2025-06-16 | 더 스크립스 리서치 인스티튜트 | 인터페론 유전자의 자극인자 sting의 비시클릭 효능제 |
| US20220380314A1 (en) | 2019-09-17 | 2022-12-01 | Bial - R&D Investments, S.A. | Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders |
| KR20220100858A (ko) | 2019-09-17 | 2022-07-18 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도 |
| AU2020349519A1 (en) | 2019-09-17 | 2022-03-17 | Bial-R&D Investments, S.A. | Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments |
| BR112022010127A2 (pt) * | 2019-11-25 | 2022-09-06 | Gain Therapeutics Sa | Compostos de arila e heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade de galatocerebrosidase |
| TWI810520B (zh) | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| JP7375214B2 (ja) | 2020-02-12 | 2023-11-07 | イーライ リリー アンド カンパニー | 置換７－（メチルアミノ）ピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037373A2 (en) | 2002-10-21 | 2004-05-06 | The Scripps Research Institute | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| EP1615697A2 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| AU2004289327A1 (en) | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease |
| US7488721B2 (en) * | 2004-05-13 | 2009-02-10 | Mcmaster University | Real time methylumbelliferone-based assay |
| EP1753422B1 (en) * | 2004-05-14 | 2008-05-28 | The Cleveland Clinic Foundation | Small molecule inhibitors for mrp1 and other multidrug transporters |
| WO2005123738A1 (en) * | 2004-06-21 | 2005-12-29 | F.Hoffmann-La Roche Ag | Pyrrazolo-pyrimidine derivatives |
| DE102005007534A1 (de) * | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| EA013525B1 (ru) | 2005-05-20 | 2010-06-30 | Алантос-Фармасьютикалз Холдинг, Инк. | Гетеробициклические ингибиторы металлопротеазы и их применение |
| US20070155737A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| EP1917262B1 (en) * | 2005-08-15 | 2011-12-14 | F. Hoffmann-La Roche AG | Piperidine and piperazine derivatives as p2x3 antagonists |
| CA2626789A1 (en) * | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| US8188097B2 (en) * | 2005-10-21 | 2012-05-29 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-A]pyrimidine compounds |
| WO2008054947A2 (en) | 2006-10-02 | 2008-05-08 | The Brigham And Women's Hospital, Inc. | Structure of acid beta-glucosidase and methods for identifying therapeutic agents |
| US20090275586A1 (en) | 2006-10-06 | 2009-11-05 | Kalypsys, Inc. | Heterocyclic inhibitors of pde4 |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| JP5586453B2 (ja) | 2007-04-13 | 2014-09-10 | アミカス セラピューティックス インコーポレイテッド | 特異的薬理シャペロンによるゴーシェ病の治療および代理マーカーを用いた治療の監視 |
| WO2008134035A1 (en) | 2007-04-27 | 2008-11-06 | Panacos Pharmaceuticals, Inc. | Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives |
| PL2154969T3 (pl) | 2007-05-16 | 2016-04-29 | Brigham & Womens Hospital Inc | Leczenie synukleinopatii |
| WO2008154207A1 (en) | 2007-06-08 | 2008-12-18 | The Burnham Institute For Medical Research | Methods and compounds for regulating apoptosis |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| WO2009049422A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP5767965B2 (ja) * | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症 |
| EP2307440A4 (en) | 2008-07-01 | 2012-12-19 | Zacharon Pharmaceuticals Inc | HEPARAN SULFATE INHIBITORS |
| WO2010086040A1 (en) * | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| EP3366688B1 (en) | 2010-12-08 | 2022-02-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
| IL252053B2 (en) * | 2014-11-06 | 2024-04-01 | Lysosomal Therapeutics Inc | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
-
2011
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/tr unknown
- 2011-12-08 PL PL18165005T patent/PL3366688T3/pl unknown
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/da active
- 2011-12-08 PL PL11810714T patent/PL2649075T3/pl unknown
- 2011-12-08 ES ES18165005T patent/ES2912284T3/es active Active
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/hu unknown
- 2011-12-08 MX MX2018000385A patent/MX385600B/es unknown
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/zh active Active
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 RS RS20220422A patent/RS63320B1/sr unknown
- 2011-12-08 MX MX2013006462A patent/MX354506B/es active IP Right Grant
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 SI SI201132052T patent/SI3366688T1/sl unknown
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/ja active Active
- 2011-12-08 PT PT118107143T patent/PT2649075T/pt unknown
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/hr unknown
- 2011-12-08 PT PT181650052T patent/PT3366688T/pt unknown
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/lt unknown
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/ru active
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
- 2011-12-08 SI SI201131532T patent/SI2649075T1/sl unknown
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/ko active Active
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/pt active IP Right Grant
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/es active Active
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
-
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
-
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
-
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
-
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259648A (en) | Pyrazolopyrimidines are converted as glucoserbrosidase activators | |
| AP3607A (en) | Substituted imidazopyridazines | |
| IL222646A0 (en) | N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives | |
| LT2534132T (lt) | Pakeistieji pirolidin-2-karboksamidai | |
| ZA201209117B (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| EP2534256A4 (en) | NEW USES | |
| IL226192A (en) | Sodium –1 h– pyrazole – 5 – olate is converted | |
| EP2541164A4 (en) | COOLER | |
| GB2490849B (en) | Di-aspirin derivatives | |
| IL225312A0 (en) | New combinations | |
| HUP1000243A2 (en) | 8-hidroxy-quinoline derivatives | |
| AU4538P (en) | H22 Grevillea juniperina | |
| AU332681S (en) | Spindle | |
| GB201008355D0 (en) | Solid supports | |
| ZA201209248B (en) | Amido-tropane derivatives | |
| IL220983A0 (en) | 2-aldoximino-5-fluoropyrimidine derivatives | |
| GB201019442D0 (en) | Novel combinations | |
| AU2010900285A0 (en) | Sparger |